Smitht Surya Bhatt News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The FDA moved the target date for their decision on the dupilumab application by 3 months, citing a need for more efficacy data from its pivotal phase 3 trials.

Surya bhattSmitht surya bhattLung imaging labUniversity of alabama at birminghamDrug administrationRegeneron pharmaceuticalBiologic license applicationEuropean medicines agencyMedicinal productsHuman usePublished february